Proventiv Therapeutics

Proventiv Therapeutics was a clinical-stage biotechnology company focused on developing therapies for the hospital and critical care markets. The company's lead candidate, PT-101, was a proprietary intravenous formulation of a dopamine receptor D1 agonist designed to prevent acute kidney injury (AKI) in patients undergoing cardiac surgery. Founded in 2016 by a team of experienced pharmaceutical executives from Mallinckrodt and Cadence Pharmaceuticals, Proventiv aimed to address significant unmet needs in perioperative care. The company's strategy involved leveraging known pharmacological pathways to create improved therapeutic options for acute clinical settings. Although the company advanced its lead program into clinical stages, it appears to have become inactive by 2020 as its leadership transitioned to other roles in the industry.